Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ningerkang Antipyretic Ice Dew is a topical symptomatic treatment developed by Hainan Bikai Pharmaceutical for the reduction of fever through physical cooling. Formulated as a liquid or gel ("Ice Dew"), it is intended for application to areas of high vascularity such as the forehead and neck. The product typically utilizes the evaporative properties of its base and the cooling effects of small molecule ingredients like menthol to lower skin temperature and provide comfort during febrile episodes. In China, it is widely used as an auxiliary treatment for fever in both pediatric and adult populations and is often categorized as a physical cooling product or medical device containing pharmaceutical active ingredients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ningerkang Antipyretic Ice Dew.